
Michal Zikan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/127734/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preoperative staging of ovarian cancer: comparison between ultrasound, <scp>CT</scp> and wholeâ€body diffusionâ€weighted <scp>MRI</scp> (<scp>ISAAC</scp> study). Ultrasound in Obstetrics and Gynecology, 2022, 59, 248-262.	1.7	11
2	Toxoplasmosis impact on prematurity and low birth weight. PLoS ONE, 2022, 17, e0262593.	2.5	10
3	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nature Communications, 2022, 13, 449.	12.8	21
4	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biology, 2022, 23, 52.	8.8	8
5	Diagnostic Reliability, Accuracy and Safety of Ultrasound-guided Biopsy and Ascites Puncture in Primarily Inoperable Ovarian Tumours. Anticancer Research, 2020, 40, 3527-3534.	1.1	7
6	Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. Cancers, 2020, 12, 956.	3.7	19
7	Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico‑pathological and molecular (next generation sequencing) study of 22�cases. Oncology Letters, 2019, 17, 2207-2214.	1.8	12
8	Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncology, The, 2019, 20, 1171-1182.	10.7	108
9	The association among cervical, anal, and oral HPV infections in high-risk and low-risk women. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 4, 100061.	1.1	9
10	A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers. Frontiers in Oncology, 2019, 9, 265.	2.8	19
11	Ultrasound characteristics of a symptomatic and asymptomatic lymphocele after pelvic and/or paraaortic lymphadenectomy. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 266-272.	1.3	7
12	A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. Gynecologic Oncology, 2018, 149, 140-145.	1.4	9
13	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 292-309.	27.6	129
14	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Modern Pathology, 2018, 31, 816-828.	5.5	46
15	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. International Journal of Cancer, 2018, 142, 1230-1243.	5.1	59
16	Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study. Ultrasound in Obstetrics and Gynecology, 2017, 49, 263-274.	1.7	33
17	Pelvic floor reconstruction by modified rectus abdominis myoperitoneal (MRAM) flap after pelvic exenterations. Gynecologic Oncology, 2017, 144, 558-563.	1.4	20
18	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	7.0	30

#	Article	IF	CITATIONS
19	The association of enchondromatosis with malignant transformed chondrosarcoma and ovarian juvenile granulosa cell tumor (Ollier disease). Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 253-257.	1.3	21
20	Sensitivity of Follow-Up Methods in Patients After Fertility-Sparing Surgery for Cervical Cancers. International Journal of Gynecological Cancer, 2017, 27, 147-153.	2.5	8
21	Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Medicine, 2017, 9, 115.	8.2	49
22	The Diagnostic Accuracy of Ultrasound in Assessment of Myometrial Invasion in Endometrial Cancer: Subjective Assessment versus Objective Techniques. BioMed Research International, 2017, 2017, 1-10.	1.9	25
23	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Medicine, 2017, 9, 116.	8.2	122
24	Prospective Evaluation of Ultrasound Accuracy in the Detection of Pelvic Carcinomatosis in Patients with Ovarian Cancer. Ultrasound in Medicine and Biology, 2016, 42, 2196-2202.	1.5	9
25	Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. Gynecologic Oncology, 2016, 143, 83-86.	1.4	35
26	Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5years of experience. Gynecologic Oncology, 2016, 142, 401-404.	1.4	24
27	Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. Expert Review of Anticancer Therapy, 2016, 16, 1311-1321.	2.4	25
28	Atypical Polypoid Adenomyoma of the Uterus. American Journal of Surgical Pathology, 2015, 39, 1148-1155.	3.7	42
29	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
30	Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Modern Pathology, 2015, 28, 1001-1010.	5.5	60
31	A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. Gynecologic Oncology, 2015, 137, 291-298.	1.4	98
32	Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 415-422.	2.8	34
33	Ovarian metastasis of clear cell renal cell carcinoma: A case report. Canadian Urological Association Journal, 2014, 8, 188.	0.6	6
34	Lymphocele: prevalence and management in gynecological malignancies. Expert Review of Anticancer Therapy, 2014, 14, 307-317.	2.4	41
35	Pelvic Lymphadenectomy Improves Survival in Patients With Cervical Cancer With Low-Volume Disease in the Sentinel Node: A Retrospective Multicenter Cohort Study. International Journal of Gynecological Cancer, 2014, 24, 303-311.	2.5	30
36	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Medicine, 2014, 6, 47.	8.2	53

#	Article	IF	CITATIONS
37	Factors affecting sonographic preoperative local staging of endometrial cancer. Ultrasound in Obstetrics and Gynecology, 2014, 43, 575-585.	1.7	42
38	DNA methylation markers for early detection of women's cancer: promise andÂchallenges. Epigenomics, 2014, 6, 311-327.	2.1	76
39	A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial. BMC Cancer, 2014, 14, 635.	2.6	12
40	Early-stage cervical cancer: Tumor delineation by magnetic resonance imaging and ultrasound — A European multicenter trial. Gynecologic Oncology, 2013, 128, 449-453.	1.4	115
41	Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer. Ultrasound in Obstetrics and Gynecology, 2013, 42, 705-712.	1.7	23
42	Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. PLoS Medicine, 2013, 10, e1001551.	8.4	135
43	The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer. PLoS Genetics, 2012, 8, e1002517.	3.5	111
44	Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. Oncologist, 2012, 17, 1515-1533.	3.7	161
45	Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecologic Oncology, 2012, 127, 462-466.	1.4	108
46	Ultrasonographic appearance of metastatic nonâ€gynecological pelvic tumors. Ultrasound in Obstetrics and Gynecology, 2012, 39, 215-225.	1.7	15
47	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	6.4	27
48	Outcomes of pregnant patients with Pap smears classified as atypical glandular cells. Cytopathology, 2012, 23, 383-388.	0.7	7
49	Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecologic Oncology, 2012, 124, 496-501.	1.4	174
50	Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy. Gynecologic Oncology, 2012, 125, 303-306.	1.4	23
51	High-risk human papillomavirus DNA in paraaortic lymph nodes in advanced stages of cervical carcinoma. Journal of Clinical Virology, 2011, 50, 46-49.	3.1	5
52	Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 559-563.	2.8	38
53	Comparative analysis of loss of heterozygosity and expression profi le in normal tissue, DCIS and invasive breast cancer. Clinical and Translational Oncology, 2011, 13, 652-655.	2.4	4
54	Oral contraceptives and risk of ovarian and breast cancers in <i>BRCA</i> mutation carriers: a meta-analysis. Expert Review of Anticancer Therapy, 2011, 11, 1197-1207.	2.4	96

#	Article	IF	CITATIONS
55	Local Control After Tailored Surgical Treatment of Early Cervical Cancer. International Journal of Gynecological Cancer, 2011, 21, 690-698.	2.5	19
56	Human Papillomavirus DNA Presence in Pelvic Lymph Nodes in Cervical Cancer. International Journal of Gynecological Cancer, 2010, 20, 126-132.	2.5	5
57	Factors Affecting Spontaneous Voiding Recovery After Radical Hysterectomy. International Journal of Gynecological Cancer, 2010, 20, 685-690.	2.5	23
58	Ultrasoundâ€guided tru ut biopsy of abdominal and pelvic tumors in gynecology. Ultrasound in Obstetrics and Gynecology, 2010, 36, 767-772.	1.7	53
59	Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. Breast Cancer Research and Treatment, 2010, 124, 337-347.	2.5	33
60	Late morbidity following nerve-sparing radical hysterectomy. Gynecologic Oncology, 2010, 116, 506-511.	1.4	54
61	Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers. Neoplasma, 2010, 57, 280-285.	1.6	7
62	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
63	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2010, 19, 2886-2897.	2.9	60
64	Hormonal contraception and risk of cancer. Human Reproduction Update, 2010, 16, 631-650.	10.8	199
65	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	2.9	99
66	Sentinel node (SLN) biopsy in the management of locally advanced cervical cancer. Gynecologic Oncology, 2009, 115, 46-50.	1.4	32
67	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. International Journal of Cancer, 2009, 125, 2214-2218.	5.1	59
68	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	6.4	15
69	Abdominal Radical Trachelectomy in Fertility-Sparing Treatment of Early-Stage Cervical Cancer. International Journal of Gynecological Cancer, 2009, 19, 1407-1411.	2.5	71
70	High-Risk Human Papillomavirus DNA in the Primary Tumor, Sentinel, and Nonsentinel Pelvic Lymph Nodes in Patients With Early-Stage Cervical Cancer. International Journal of Gynecological Cancer, 2009, 19, 703-707.	2.5	14
71	Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors. International Journal of Gynecological Cancer, 2008, 18, 833-837.	2.5	41
72	Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. International Journal of Gynecological Cancer, 2008, 18, 766-772.	2.5	119

#	Article	IF	CITATIONS
73	Novel complex genomic rearrangement of the BRCA1 gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 637, 205-208.	1.0	5
74	<i>AURKA</i> F311 Polymorphism and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	2.5	30
75	RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	6.2	217
76	Localization of the Sentinel Node of the Upper Outer Breast Quadrant in the Axillary Quadrants. Annals of Surgical Oncology, 2007, 14, 633-637.	1.5	11
77	High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer. Journal of Genetics, 2007, 86, 169-171.	0.7	5
78	Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Human Mutation, 2005, 25, 319-319.	2.5	21
79	Mutational analysis of theBRCA1 gene in 30 Czech ovarian cancer patients. Journal of Genetics, 2005, 84, 63-67.	0.7	8
80	High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Research, 2005, 7, R728-36.	5.0	59
81	Mutations of the <i>BRCA1</i> Gene in Hereditary Breast and Ovarian Cancer in the Czech Republic. Medical Principles and Practice, 2003, 12, 23-29.	2.4	22